Wednesday starts with Admiral William McRaven and wraps with a fireside chat with FDA Commissioner Robert Califf, always an interesting speaker and an important figure to hear from. In between we’ll feature sessions on AI in drug discovery and obesity therapeutics. Check it all out below.
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.
The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.
When the primary patent on a blockbuster drug expires, affordable generic or biosimilar competition is expected to balance the market, offering relief to patients who could not afford the h
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
For the sixth year running the PM Society will be bringing their ‘A Career in Pharmaceutical and Healthcare Communications’ event back to the Royal Society of Medicine.
Unravel Complex TME Biology, Optimize Payload Delivery, & Overcome Early Risks in Developing Advanced Logic Gated & Dual-Targeted Cell Therapies
